SAFETY DATA SHEETS

This SDS packet was issued with item:

078677154

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078677139 078677147 078677162

SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg

Trade Name: SIMPLICEF
Synonyms: Cefpodoxime Proxetil Tablets
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.
100 Campus Drive, P.O. Box 651
Florham Park, New Jersey 07932 (USA)
Rocky Mountain Poison Control Center Phone: 1-866-531-8896
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.
Mercuriusstraat 20
1930 Zaventem
Belgium

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: VMIPSrecords@zoetis.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance: Orange tablets

Classification of the Substance or Mixture

GHS - Classification

Respiratory Sensitization: Category 1
Skin Sensitization: Category 1

EU Classification:

EU Indication of danger: Xn - Harmful
Irritant; (Xi)
EU Risk Phrases:
R42/43 - May cause sensitization by inhalation and skin contact.

Label Elements

Signal Word: Danger
Hazard Statements: H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled
H317 - May cause an allergic skin reaction

Precautionary Statements:

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P284 - Wear respiratory protection
P272 - Contaminated work clothing should not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P304 + P340 - IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTRE or doctor/physician
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P321 - Specific treatment (see supplemental first aid instructions on this label)
P362 - Take off contaminated clothing and wash before reuse
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards

Short Term: May cause stomach irritation, diarrhea, nausea, or vomiting. Individuals who are sensitive to beta lactam antibiotics, both penicillins and cephalosporins, may experience contact or systemic hypersensitivity and anaphylaxis upon exposure to this drug.

Known Clinical Effects: Hypersensitivity reactions may also occur in susceptible individuals. May cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur.

Australian Hazard Classification (NOHSC): Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Cefpodoxime Proxetil	87239-81-4	Not Listed	Xn;R42/43	Resp.Sens.1,H334 Skin Sens. 1,H317	30.3
Sodium Lauryl Sulfate	151-21-3	205-788-1	Not Listed	Not Listed	*
Magnesium Stearate	557-04-0	209-150-3	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Dike and collect water used to fight fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Keep away from heat, sparks, and flame.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Cefpodoxime Proxetil

Zoetis OEL TWA 8-hr	100µg/m^3 Sensitizer

Magnesium Stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Lithuania OEL - TWA	5 mg/m^3
Sweden OEL - TWAs	5 mg/m^3

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	**Color:**	Orange
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

9. PHYSICAL AND CHEMICAL PROPERTIES

Partition Coefficient: (Method, pH, Endpoint, Value)
No data available
Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:
- **Autoignition Temperature (Solid) (°C):** No data available
- **Flammability (Solids):** No data available
- **Flash Point (Liquid) (°C):** No data available
- **Upper Explosive Limits (Liquid) (% by Vol.):** No data available
- **Lower Explosive Limits (Liquid) (% by Vol.):** No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable at normal conditions
Possibility of Hazardous Reactions
- **Oxidizing Properties:** No data available
- **Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.
- **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers
- **Hazardous Decomposition Products:** No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients. Toxicological properties of the formulation have not been investigated.

Acute Toxicity: (Species, Route, End Point, Dose)

Cefpodoxime Proxetil
Mouse Oral LD 50 > 8000 mg/kg
Mouse Sub-tenon injection (eye) LD 50 2535mg/kg
Mouse Subcutaneous LD 50 > 10,000mg/kg
Rat Intravenous LD 50 > 4000mg/kg

Lactose Monohydrate
Rat Oral LD 50 29700 mg/kg

Sodium Lauryl Sulfate
Rat Oral LD 50 1288 mg/kg
Rat Sub-tenon injection (eye) LD 50 210mg/kg
Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

11. TOXICOLOGICAL INFORMATION

Irritation / Sensitization: (Study Type, Species, Severity)

Cefpodoxime Proxetil
Eye Irritation Rabbit Minimal
Skin Irritation Rabbit No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Magnesium Stearate
13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Sodium Lauryl Sulfate
3 Day(s) Rat Oral 75 mg/kg LOAEL Liver, Blood

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Cefpodoxime Proxetil
Reproductive & Fertility Rat Oral >500 mg/kg/day NOAEL Fertility
Reproductive & Fertility Rabbit Oral > 500 mg/kg/day NOAEL Fertility
Embryo / Fetal Development Rat Oral 100 mg/kg/day NOAEL Not Teratogenic, Fetotoxicity
Embryo / Fetal Development Rabbit Oral 30 mg/kg/day NOAEL Not Teratogenic, Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Cefpodoxime Proxetil
Bacterial Mutagenicity (Ames) *Salmonella* Negative
Chromosome Aberration Negative
Unscheduled DNA Synthesis Negative
In Vivo Micronucleus Negative

Lactose Monohydrate
In Vitro Bacterial Mutagenicity (Ames) Negative

Water
Bacterial Mutagenicity (Ames) Negative
In Vivo Dominant Lethal Assay Drosophila Negative
In Vivo Micronucleus Mouse Rat Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A
Class D, Division 2, Subdivision B

15. REGULATORY INFORMATION

Cefpodoxime Proxetil

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Sodium Lauryl Sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	205-788-1

Magnesium Stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

H317 - May cause an allergic skin reaction
H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled

Xn - Harmful
Xi - Irritant

R42/43 - May cause sensitization by inhalation and skin contact.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet